Status:
COMPLETED
Functional MRI of Hypoxia-mediated Rectal Cancer Aggressiveness
Lead Sponsor:
University Hospital, Akershus
Collaborating Sponsors:
Oslo University Hospital
University of Oslo
Conditions:
Rectal Diseases
Rectal Neoplasms
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this study is to establish a reliable method for detection of rectal cancer patients with aggressive tumor at risk of metastatic disease and death by functional MRI.
Eligibility Criteria
Inclusion
- The patient is willing and able to give full written consent according to the protocol approved by the Regional Ethics Committee.
- The patient has confirmed rectal cancer diagnosis and is scheduled to radical surgery alone or preoperative CRT followed by surgery.
- The patient is ≥ 18 years.
- The patient has no prior rectal cancer treatment.
- The patient has adequate renal function: creatinine clearance ≥ 60 ml/minute.
- The patient has signed the written informed consent according to the protocol approved by the Regional Ethics Committee.
Exclusion
- The patient has contraindication to MRI or MRI contrast agent according to clinical practice.
- The patient wants to withdraw for any reason during the study.
Key Trial Info
Start Date :
October 1 2013
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2017
Estimated Enrollment :
192 Patients enrolled
Trial Details
Trial ID
NCT01816607
Start Date
October 1 2013
End Date
December 1 2017
Last Update
November 19 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Akershus University Hospital
Lørenskog, Akershus, Norway, 1478